While immunotherapy has become a cornerstone in the management of advanced NSCLC, particularly in tumors expressing PD-L1 or lacking actionable driver mutations, its role in SCLC differs substantially and is influenced by distinct tumor biology and immune microenvironment features. Here, CD274 is linked to neoplasm.